Predictive Oncology (POAI)
(Delayed Data from NSDQ)
$0.96 USD
-0.02 (-1.92%)
Updated Aug 9, 2024 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
POAI 0.96 -0.02(-1.92%)
Will POAI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for POAI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for POAI
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
Predictive Oncology looks to raise $1.3M through exercise of warrants
Predictive Oncology announces exercise of warrants for $1.26M in gross proceeds